Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Systemic Mastocytosis
NCT00979160Phase 2Unknown
- Sponsor
- University of Naples Federico II
- Start
- Nov 2009
- Primary completion
- Dec 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in systemic mastocytosis (SM), sponsored by University of Naples Federico II. Primary endpoint: Clinical Response Rate (B/C findings and mediator-related symptoms) at 12 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT00979160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00979160.